Sunday, March 22, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

EU regulators reaffirm AstraZeneca/Oxford Covid-19 vaccine

After more than a dozen European countries stopped distribution of the AstraZeneca/Oxford Covid-19 vaccine due to concerns about blood clots, the European Union’s top pharmaceutical regulator on Thursday concluded the vaccine was safe.

“The committee has come to a clear scientific conclusion: This is a safe and effective vaccine. Its benefits in protecting people from Covid-19 with the associated risks of deaths and hospitalizations outweigh the possible risks,” said Emer Cooke, executive director of the European Medicines Agency (EMA), during a press conference. “The committee also concluded that the vaccine is not associated with an increase in the overall risk of thromboembolic events or blood clots.”

The agency’s guidance echoed that of the World Health Organization, which said on Wednesday that “the benefits of the AstraZeneca [Covid-19] vaccine outweigh its risks” and recommended that vaccinations continue.

The two public health heavyweights were forced to weigh in after several reports surfaced in Europe of severe side effects such as bleeding and blood clots (also known as thrombosis) in patients earlier this month following injections of the Covid-19 vaccine developed by the pharmaceutical giant AstraZeneca and the University of Oxford. The cases emerged out of more than 17 million recipients of the vaccine between the United Kingdom and the EU to date.

The complications of concern so far are rare, with 37 reported cases.

Source: VOX

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!